CU20130065A7 - Derivados de indol - Google Patents
Derivados de indolInfo
- Publication number
- CU20130065A7 CU20130065A7 CUP2013000065A CU20130065A CU20130065A7 CU 20130065 A7 CU20130065 A7 CU 20130065A7 CU P2013000065 A CUP2013000065 A CU P2013000065A CU 20130065 A CU20130065 A CU 20130065A CU 20130065 A7 CU20130065 A7 CU 20130065A7
- Authority
- CU
- Cuba
- Prior art keywords
- indol derivatives
- derivatives
- bradykinin
- racemates
- painful
- Prior art date
Links
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical class C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 title 1
- 101800004538 Bradykinin Proteins 0.000 abstract 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 abstract 1
- 102100035792 Kininogen-1 Human genes 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 229940054051 antipsychotic indole derivative Drugs 0.000 abstract 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000002475 indoles Chemical class 0.000 abstract 1
- 230000004968 inflammatory condition Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
- 239000008196 pharmacological composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
La presente invención se refiere a los derivados de indol de la fórmula (I), en donde R^1-R^6 y X son tal como se define en las reivindicaciones y antípodos o racematos ópticos y sales y/o de los mismos, que son antagonistas selecctivos de bradiquinina B1 para el proceso para producir estos compuestos, composiciones farmacolcógicas que los contienen y a su uso en terapia o prevención de condiciones dolorosas e inflamatorias.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU1000598A HUP1000598A2 (en) | 2010-11-05 | 2010-11-05 | Indole derivatives |
| PCT/HU2011/000104 WO2012059776A1 (en) | 2010-11-05 | 2011-11-04 | Indole derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CU20130065A7 true CU20130065A7 (es) | 2013-07-31 |
| CU24136B1 CU24136B1 (es) | 2015-11-27 |
Family
ID=89990047
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU20130065A CU24136B1 (es) | 2010-11-05 | 2011-11-04 | Derivados de indol |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20130217702A1 (es) |
| EP (1) | EP2635567B1 (es) |
| JP (1) | JP2013542951A (es) |
| KR (1) | KR20130130733A (es) |
| CN (1) | CN103201276B (es) |
| AP (1) | AP2013006867A0 (es) |
| AU (1) | AU2011324958A1 (es) |
| BR (1) | BR112013011192A2 (es) |
| CA (1) | CA2812655A1 (es) |
| CU (1) | CU24136B1 (es) |
| EA (1) | EA022939B1 (es) |
| HU (2) | HUP1000598A2 (es) |
| IL (1) | IL225393A0 (es) |
| MX (1) | MX2013005050A (es) |
| NZ (1) | NZ610699A (es) |
| PH (1) | PH12013500588A1 (es) |
| SG (1) | SG189833A1 (es) |
| WO (1) | WO2012059776A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3558972A1 (en) | 2016-12-23 | 2019-10-30 | Bayer Pharma Aktiengesellschaft | Tetrazole containing compounds |
| JOP20190156B1 (ar) * | 2016-12-23 | 2023-09-17 | Bayer Pharma AG | أميدات عطرية لحمض الكربوكسيليك بصفتها مضادات لمستقبلة البراديكينين b1 |
| US12023319B2 (en) | 2016-12-23 | 2024-07-02 | Bayer Pharma Aktiengesellschaft | Carboxylic acid aromatic amides |
| CN112573978B (zh) * | 2019-09-30 | 2022-05-13 | 北京大学 | 一种芳基卤化物的高效卤化合成方法 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ227841A (en) | 1988-02-12 | 1991-08-27 | Merck Sharp & Dohme | Heterocyclic compounds with at least two non-condensed five membered rings and pharmaceutical compositions |
| GB9716656D0 (en) | 1997-08-07 | 1997-10-15 | Zeneca Ltd | Chemical compounds |
| FR2822827B1 (fr) | 2001-03-28 | 2003-05-16 | Sanofi Synthelabo | Nouveaux derives de n-(arylsulfonyl) beta-aminoacides comportant un groupe aminomethyle substitue, leur procede de preparation et les compositions pharmaceutiques en contenant |
| AU2002346048A1 (en) | 2001-06-07 | 2002-12-16 | Merck And Co., Inc. | Benzodiazepine bradykinin antagonists |
| WO2003000657A1 (en) | 2001-06-20 | 2003-01-03 | Daiichi Pharmaceutical Co., Ltd. | Diamine derivatives |
| US6919343B2 (en) * | 2002-02-08 | 2005-07-19 | Merck & Co., Inc. | N-biphenyl(substituted methyl) aminocycloalkane-carboxamide derivatives |
| EP1545538A2 (en) * | 2002-08-29 | 2005-06-29 | Merck & Co., Inc. | N-biarylmethyl aminocycloalkanecarboxamide derivatives |
| US6908921B2 (en) | 2002-12-13 | 2005-06-21 | Merck & Co., Inc. | Quinoxalinone derivatives as bradykinin B1 antagonists |
| WO2005004810A2 (en) | 2003-07-02 | 2005-01-20 | Merck & Co., Inc. | Arylsulfonamide derivatives |
| CN1832922A (zh) * | 2003-08-07 | 2006-09-13 | 默克公司 | 磺酰基取代的n－(联芳基甲基)氨基环丙烷甲酰胺类 |
| EP1654232A4 (en) * | 2003-08-07 | 2008-11-12 | Merck & Co Inc | SULPHONYL SUBSTITUTED N- (BIARYLMETHYL) AMINOCYCLOPROPANCARBOXYLIC ACID AMIDE |
| DE602005012806D1 (en) * | 2004-03-02 | 2009-04-02 | Merck & Co Inc | Aminocyclopropancarbonsäureamidderivate als bradykininantagonisten |
| US7517899B2 (en) | 2004-03-30 | 2009-04-14 | Wyeth | Phenylaminopropanol derivatives and methods of their use |
| CA2568914C (en) | 2004-06-04 | 2013-09-24 | Affinium Pharmaceuticals, Inc. | Therapeutic agents, and methods of making and using the same |
| EP1799677A1 (en) | 2004-10-08 | 2007-06-27 | Ranbaxy Laboratories Limited | Oxazolidinone derivatives as antimicrobials |
| PT1912976E (pt) | 2005-07-21 | 2009-01-07 | Hoffmann La Roche | Derivados de indol-3-il-carboni-piperidin-benzimidazole como antagonistas dos receptores v1a |
| FR2894964B1 (fr) * | 2005-12-19 | 2008-02-22 | Cerep Sa | Composes a base de quatre cycles aromatiques, preparation et utilisations |
| WO2007101007A2 (en) | 2006-02-23 | 2007-09-07 | Neurogen Corporation | Aryl sulfonyl heterocycles |
| DE102007034620A1 (de) | 2007-07-25 | 2009-01-29 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue B1-Antagonisten |
| AR068509A1 (es) | 2007-09-19 | 2009-11-18 | Jerini Ag | Antagosnistas del receptor de bradiquinina b1 |
| WO2009124733A1 (de) | 2008-04-08 | 2009-10-15 | Gruenenthal Gmbh | Substituierte sulfonamid-derivate |
| CA2722704A1 (en) * | 2008-04-28 | 2009-11-05 | Zalicus Pharmaceuticals Ltd. | Cyclylamine derivatives as calcium channel blockers |
| WO2010097372A1 (de) * | 2009-02-26 | 2010-09-02 | Boehringer Ingelheim International Gmbh | Verbindungen als bradykinin-b1-antagonisten |
-
2010
- 2010-11-05 HU HU1000598A patent/HUP1000598A2/hu unknown
-
2011
- 2011-11-04 EP EP11788570.7A patent/EP2635567B1/en active Active
- 2011-11-04 SG SG2013025226A patent/SG189833A1/en unknown
- 2011-11-04 KR KR1020137014219A patent/KR20130130733A/ko not_active Withdrawn
- 2011-11-04 JP JP2013537214A patent/JP2013542951A/ja active Pending
- 2011-11-04 NZ NZ610699A patent/NZ610699A/en not_active IP Right Cessation
- 2011-11-04 CU CU20130065A patent/CU24136B1/es unknown
- 2011-11-04 AP AP2013006867A patent/AP2013006867A0/xx unknown
- 2011-11-04 MX MX2013005050A patent/MX2013005050A/es active IP Right Grant
- 2011-11-04 PH PH1/2013/500588A patent/PH12013500588A1/en unknown
- 2011-11-04 WO PCT/HU2011/000104 patent/WO2012059776A1/en not_active Ceased
- 2011-11-04 CN CN201180053024.8A patent/CN103201276B/zh not_active Expired - Fee Related
- 2011-11-04 HU HUE11788570A patent/HUE026652T2/en unknown
- 2011-11-04 US US13/823,221 patent/US20130217702A1/en not_active Abandoned
- 2011-11-04 BR BR112013011192A patent/BR112013011192A2/pt not_active IP Right Cessation
- 2011-11-04 CA CA2812655A patent/CA2812655A1/en not_active Abandoned
- 2011-11-04 AU AU2011324958A patent/AU2011324958A1/en not_active Abandoned
- 2011-11-04 EA EA201300541A patent/EA022939B1/ru not_active IP Right Cessation
-
2013
- 2013-03-21 IL IL225393A patent/IL225393A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2635567A1 (en) | 2013-09-11 |
| MX2013005050A (es) | 2013-12-06 |
| EA022939B1 (ru) | 2016-03-31 |
| KR20130130733A (ko) | 2013-12-02 |
| PH12013500588A1 (en) | 2015-11-06 |
| NZ610699A (en) | 2015-08-28 |
| CN103201276B (zh) | 2015-02-25 |
| CN103201276A (zh) | 2013-07-10 |
| AU2011324958A1 (en) | 2013-06-06 |
| EA201300541A1 (ru) | 2013-08-30 |
| AP2013006867A0 (en) | 2013-05-31 |
| JP2013542951A (ja) | 2013-11-28 |
| IL225393A0 (en) | 2013-06-27 |
| EP2635567B1 (en) | 2015-10-28 |
| HUE026652T2 (en) | 2016-07-28 |
| CA2812655A1 (en) | 2012-05-10 |
| SG189833A1 (en) | 2013-06-28 |
| HUP1000598A2 (en) | 2012-09-28 |
| BR112013011192A2 (pt) | 2016-08-02 |
| US20130217702A1 (en) | 2013-08-22 |
| HU1000598D0 (en) | 2010-12-28 |
| CU24136B1 (es) | 2015-11-27 |
| WO2012059776A1 (en) | 2012-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP19011216A (es) | Inhibidores de piridopyrimdinona cdk2/4/6 | |
| CU20090070A7 (es) | Nuevos derivados de sulfonamida como antagonistas de la bradiquinina | |
| CR20120410A (es) | Pirrolidina-2-carboxamidas sustituidas | |
| UY34960A (es) | Dihidropiridona p1 como inhibidores del factor xia | |
| CR20140089A (es) | Nuevos derivados bicíclicos de dihidroquinolina-2-ona | |
| UY34959A (es) | Dihidropiridona p1 como inhibidores del factor xia | |
| ECSP16016726A (es) | Derivados de quinolizina sustituidos útiles como inhibidores de integrasa del vih | |
| UY35898A (es) | ?compuestos inhibidores de syk y composiciones que los comprenden?. | |
| CO6771439A2 (es) | Inhibidores de benzodioxano de la producción de leucotrieno | |
| CR20110099A (es) | Pirrolidina-2-carboxamidas sustituidas | |
| CU20090064A7 (es) | Nuevos derivados de benzamida como antagonistas de la bradiquinina | |
| ECSP15012804A (es) | Alcoxipirazoles como activadores de guanilato ciclasa soluble | |
| MX2014002770A (es) | Nuevos derivados dihidroquinolina-2-ona. | |
| CO6321282A2 (es) | Derivados de piperidinilindol como inhibidores de aldosterona sintasa | |
| CU20140072A7 (es) | Derivados de dihidro-oxazina y dihidro-pirido-oxazina | |
| SV2010003598A (es) | Derivados de tiazol usados como inhibidores de pi 3-cinasa | |
| ECSP10010434A (es) | Inhibidores de hsp90 | |
| DOP2014000036A (es) | Compuestos de piridazinona y su uso como inhibidores daao | |
| CR20140071A (es) | Nuevos compuestos de 4-piperidinilo para uso como inhibidores de la tankirasa | |
| UY32077A (es) | Inhibidores de quinasa tipo polo | |
| UY35551A (es) | Derivados heteroarilos como inhibidores de aldosterona sintasa | |
| UY33655A (es) | Co-cristales y sales de inhibidores de ccr30 | |
| ECSP13012548A (es) | Inhibidores de oxadiazol de la producción de leucotrienos. | |
| CU20100073A7 (es) | Nuevos derivados no peptídicos como antagonistas b1 de la bradiquinina | |
| NI201100035A (es) | Agentes antifúngicos. |